NCT02792400

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University Hospital, Gentofte, Copenhagen · Academic / Other
• Sex: All
• Age: 30 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production. Patients with type 2 diabetes exhibit elevated plasma glucagon levels in the fasting state, and in response to ingestion of glucose or a mixed meal.glucagon, glucagon concentrations fail to decrease appropriately and may even increase. This diabetic hyperglucagonaemia may therefore contribute importantly to the hyperglycaemia of the patients. Several glucose-lowering treatment modalities have been shown to affect glucagon levels in patients with type 2 diabetes, but the role of glucagon in the glucose-lowering effects of these treatment modalities has been difficult to discern. By using a glucagon receptor antagonist (GRA) the investigators will exploit glucagon receptor antagonism to delineate the role of glucagon during treatment with sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors, which have been shown to increase and decrease plasma glucagon levels, respectively.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	LY2403021	Glucagon receptor antagonist
DRUG	LY2403021 placebo
PROCEDURE	Standardised liquid meal
DRUG	Linagliptin	DPP-4-inhibitor
DRUG	Linagliptin placebo
DRUG	Empagliflozin	SGLT2-inhibitor
DRUG	Empagliflozin placebo

Timeline

• Start date: 2016-05-01
• Primary completion: 2016-08-01
• Completion: 2018-07-01
• First posted: 2016-06-07
• Last updated: 2020-04-08

Locations

1 site across 1 country: Denmark